p.84 抽出テキスト

PREVENT equations. Circulation 2024;149:430–49. https://doi.org/10. 1161/CIRCULATIONAHA.123.067626 82. SCORE2 Writing Group; European Society of Cardiology’s Cardiovascular Risk Collaboration (CRC) Unit. Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model. Eur Heart J 2026. https://doi.org/10.1093/eurheartj/ehag154 83. Reitsma TH, Lim CE, Gynnild MN, Kaptoge S, Loo L, Holtrop J, et al. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. Eur Heart J 2026. https://doi.org/10.1093/ eurheartj/ehag153 84. Zhang S, Marken I, Stubbendorff A, Ericson U, Qi L, Sonestedt E, et al. The EAT-Lancet diet index, plasma proteins, and risk of heart failure in a population-based cohort. JACC Heart Fail 2024;12:1197–208. https://doi. org/10.1016/j.jchf.2024.02.017 85. Zhu Z, Li FR, Jia Y, Li Y, Guo D, Chen J, et al. Association of lifestyle with incidence of heart failure according to metabolic and genetic risk status: a population-based prospective study. Circ Heart Fail 2022;15:e009592. https://doi.org/10.1161/CIRCHEARTFAILURE.122.009592 86. Ibsen DB, Chiu YH, Gemes K, Wolk A. Hypothetical 22-year intervention with the Dietary Approaches to Stop Hypertension and risk of heart failure in a general population. Am J Epidemiol 2024;193:96–106. https://doi.org/10. 1093/aje/kwad181 87. Ibsen DB, Levitan EB, Akesson A, Gigante B, Wolk A. The DASH diet is associated with a lower risk of heart failure: a cohort study. Eur J Prev Cardiol 2022;29:1114–23. https://doi.org/10.1093/eurjpc/zwac003 88. Strengers JG, den Ruijter HM, Boer JMA, Asselbergs FW, Verschuren WMM, van der Schouw YT, et al. The association of the Mediterranean diet with heart failure risk in a Dutch population. Nutr Metab Cardiovasc Dis 2021; 31:60–66. https://doi.org/10.1016/j.numecd.2020.08.003 89. Papadaki A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, Salas-Salvado J, Corella D, et al. Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. Eur J Heart Fail 2017;19:1179–85. https://doi.org/10.1002/ejhf.750 90. Larsson SC, Tektonidis TG, Gigante B, Akesson A, Wolk A. Healthy lifestyle and risk of heart failure: results from 2 prospective cohort studies. Circ Heart Fail 2016;9:e002855. https://doi.org/10.1161/CIRCHEARTFAILURE. 115.002855 91. LaMonte MJ, LaCroix AZ, Nguyen S, Evenson KR, Di C, Stefanick ML, et al. Accelerometer-measured physical activity, sedentary time, and heart failure risk in women aged 63 to 99 years. JAMA Cardiol 2024;9:336–45. https://doi. org/10.1001/jamacardio.2023.5692 92. Jung I, Kwon H, Park SE, Han KD, Park YG, Rhee EJ, et al. Changes in patterns of physical activity and risk of heart failure in newly diagnosed diabetes mellitus patients. Diabetes Metab J 2022;46:327–36. https://doi.org/10.4093/ dmj.2021.0046 93. Rariden BS, Boltz AJ, Brawner CA, Pinkstaff SO, Richardson MR, Johnson TM, et al. Sedentary time and cumulative risk of preserved and reduced ejection fraction heart failure: from the Multi-Ethnic Study of Atherosclerosis. J Card Fail 2019;25:418–24. https://doi.org/10.1016/j. cardfail.2019.03.017 94. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17–96. https://doi.org/10.1093/eurheartj/ ehaa605 95. Yoo JE, Jeong SM, Yeo Y, Jung W, Yoo J, Han K, et al. Smoking cessation reduces the risk of heart failure: a nationwide cohort study. JACC Heart Fail 2023;11:277–87. https://doi.org/10.1016/j.jchf.2022.07.006 96. Ding N, Shah AM, Blaha MJ, Chang PP, Rosamond WD, Matsushita K. Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction. J Am Coll Cardiol 2022;79:2298–305. https://doi. org/10.1016/j.jacc.2022.03.377 97. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol 2019;26:279–88. https://doi.org/10.1177/ 2047487318806658 98. Andersson C, Schou M, Gustafsson F, Torp-Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: consensus and controversy. Circ Heart Fail 2022;15:e009459. https://doi.org/10.1161/ CIRCHEARTFAILURE.121.009459 99. Abdullah R, Bjornebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, et al. Severe biventricular cardiomyopathy in both current and former longterm users of anabolic-androgenic steroids. Eur J Prev Cardiol 2024;31: 599–608. https://doi.org/10.1093/eurjpc/zwad362 100. Arenas DJ, Beltran S, Zhou S, Goldberg LR. Cocaine, cardiomyopathy, and heart failure: a systematic review and meta-analysis. Sci Rep 2020;10: 19795. https://doi.org/10.1038/s41598-020-76273-1 101. Schurer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail 2017;5: 435–45. https://doi.org/10.1016/j.jchf.2017.02.017 102. Group SR, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 2021;384:1921–30. https://doi.org/10.1056/NEJMoa1901281 103. Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2024;12:447–61. https://doi. org/10.1016/S2213-8587(24)00102-5 104. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788–801. https://doi.org/10.1016/S0140-6736(22)02074-8 105. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–84. https://doi.org/10.1093/eurheartj/ehab777 106. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–29. https://doi.org/10.1056/NEJMoa2025845 107. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385:2252–63. https://doi.org/10.1056/ NEJMoa2110956 108. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 2022;24:996–1005. https://doi.org/10. 1002/ejhf.2469 109. Yang R, Lv J, Yu C, Guo Y, Bian Z, Han Y, et al. Importance of healthy lifestyle factors and ideal cardiovascular health metrics for risk of heart failure in Chinese adults. Int J Epidemiol 2022;51:567–78. https://doi.org/10.1093/ ije/dyab236 110. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation 2025;151:828–34. https://doi.org/10.1161/ CIRCULATIONAHA.124.071117 111. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Picard MH, Hutter AM Jr, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 2010;3:472–6. https://doi.org/10.1161/ CIRCHEARTFAILURE.109.931063 112. Richards JR, Harms BN, Kelly A, Turnipseed SD. Methamphetamine use and heart failure: prevalence, risk factors, and predictors. Am J Emerg Med 2018; 36:1423–8. https://doi.org/10.1016/j.ajem.2018.01.001 113. Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, et al. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation 2019;140:1613–22. https://doi.org/10. 1161/CIRCULATIONAHA.119.041659 114. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol 2020;75:1128–41. https:// doi.org/10.1016/j.jacc.2019.12.063 115. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816 116. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–27. https://doi.org/10.1056/ NEJMoa2204233 117. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–306. https://doi.org/10.1056/ NEJMoa1811744 118. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314–414. https://doi.org/10.1093/ eurheartj/ehae176 119. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026